Regeneron Pharmaceuticals, Inc. (REGN) Stock Valuation — PE Analysis
Biotechnology · NASDAQ
Current Price
$612.14
PE Ratio (TTM)
14.4x
Intrinsic Value
$822.95
+25.6% margin of safety
COMPETITIVE MOAT
↑Dupixent & Eylea HD Dominance
Strong sales growth from Dupixent and Eylea HD in Q1 demonstrates significant market penetration and patient adoption. These blockbuster drugs provide a substantial revenue stream and competitive advantage.
↑Pipeline Expansion in Oncology
The expanded CytomX deal for bispecific cancer therapies, with potential milestones up to $4 billion, highlights Regeneron's commitment to innovation. This strategic move aims to secure future growth in a high-demand therapeutic area.
↑Proprietary Technology Platform
Regeneron's established genetic engineering and antibody discovery technologies, like VelocImmune, are a core strength. This platform enables the efficient development of novel therapeutics, creating a barrier to entry for competitors.
INVESTMENT RISKS
↓Eylea Sales Decline & Competition
The plunge in Eylea sales and intensifying competition pose a significant threat. This erosion of a key revenue driver could impact overall financial performance and market position.
↓Investor Lawsuits
Ongoing investigations by law firms like Pomerantz LLP suggest potential investor concerns. Such legal actions can lead to reputational damage and financial liabilities.
↓Pipeline Execution Uncertainty
While the pipeline shows promise, the success of new drug candidates in metabolic, ophthalmology, and rare diseases is not guaranteed. Clinical trial failures or regulatory hurdles could derail future growth.
Base case
REGN base case PE valuation
A base case PE valuation for REGN estimates a fair value of about $822.95 per share, against a current price of $612.14. The model assumes 10.4% annual earnings growth, a 14x target PE multiple, and a 10% discount rate.
Intrinsic Value
$822.95
Margin of safety
+25.6%
Expected annual return
+6.1%
Base case assumptions: 10.4% annual earnings growth, 14x target PE, 10% discount rate, 5 year projection. Data as of 2026-06-12.
This base case uses default assumptions and is not financial advice. The fair value changes significantly when the target PE or earnings growth rate changes. Open the calculator to set your own assumptions and see the full sensitivity range.
Customize the REGN PE valuation
Adjust the target PE, earnings growth, and discount rate to see how the fair value and margin of safety for Regeneron Pharmaceuticals, Inc. respond.
Open PE Calculator for REGNCompany Overview
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.
Financial Metrics — REGN PE Stock Valuation Data
PE Ratio (TTM)
14.4x
PEG Ratio
7.81
Earnings Yield
6.95%
ROE (TTM)
14.3%
Revenue/Share (TTM)
$143.46
Dividend Yield
0.59%
Debt/Equity
0.09x
Frequently Asked Questions
What is the PE ratio of REGN?
The trailing twelve-month PE ratio of REGN reflects how much investors pay per dollar of Regeneron Pharmaceuticals, Inc.'s earnings. This metric is most useful when compared to Biotechnology peers and the company's own historical range.
Is REGN overvalued based on PE ratio?
REGN's PE of 14.4x combined with a PEG ratio of 7.81 provides a growth-adjusted perspective. A PEG above 2.0 suggests REGN may be richly valued even accounting for growth. Keep in mind that PE-based valuation works best for profitable, mature companies — for high-growth or cyclical Biotechnology, a DCF analysis may be more appropriate.
How do I value REGN stock using PE ratio?
To value Regeneron Pharmaceuticals, Inc. using PE: (1) Compare the current PE (14.4x) against the Biotechnology median to assess relative pricing, (2) check the PEG ratio (7.81) to adjust for growth expectations, (3) review the 5-year PE range to identify where the stock sits historically, and (4) estimate fair value by multiplying a target PE by forward EPS estimates. This relative approach complements DCF's absolute valuation.
What is the PEG ratio of REGN?
REGN's PEG ratio is 7.81, calculated by dividing the PE ratio (14.4x) by the expected earnings growth rate. A PEG above 2.0 often signals the stock is priced aggressively relative to its growth trajectory. Note that PEG accuracy depends on the reliability of growth estimates.
Should I use PE ratio or DCF for REGN stock valuation?
PE ratio gives a quick relative read — how REGN is priced versus Biotechnology peers. DCF provides an absolute value based on projected free cash flows. For the most reliable valuation, use PE as a quick comparability screen and DCF for a deeper fundamental analysis. Each method has blind spots: PE ignores capital structure and cash flow quality, while DCF is sensitive to growth and discount rate assumptions.
Learn More
- See REGN DCF Valuation → — Intrinsic value via Discounted Cash Flow analysis
- PE Methodology — Step-by-step guide to PE ratio stock valuation
- DCF Methodology — Guide to discounted cash flow analysis
- PE Ratio — Understanding the price-to-earnings ratio
- Intrinsic Value — How to evaluate stock fair value
Related PE Valuations
All Healthcare valuationsP/E and DCF value REGN with different methods and assumptions, so the two conclusions can differ. Compare the DCF intrinsic value.
Price as of 2026-06-12. Financial data from Financial Modeling Prep (trailing twelve months) · Valuation methodology by Charlie Wang.
This is an estimate, not investment advice.